Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152693 | 0.85 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4MAP2K1 | |
| SCHEMBL5152692 | 0.84 | CHRNA3 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4PRKAB2 | |
| SCHEMBL5152285 | 0.84 | CHRNB4 (0.54) | CHRNB4CHRNA3CHRNB2CHRNA4MAP2K1 | |
| SCHEMBL5151446 | 0.81 | CHRNB4 (0.50) | CHRNB4CHRNA3 | |
| SCHEMBL5155424 | 0.78 | LTA4H (0.58) | CHRNB4CHRNA3LTA4H | |
| Hydrochloric Acid SCHEMBL5153253 | 0.77 | LTA4H (0.57) | CHRNA3LTA4H | |
| SCHEMBL26999492 | 0.77 | CHRNB4 (0.63) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL29039262 | 0.77 | CHRNB4 (0.63) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL5151779 | 0.74 | CHRNA3 (0.47) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| SCHEMBL5150203 | 0.74 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | CHRNB4 1566/4885CHRNA3 2171/4885CHRNB2 3662/4885 |
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | CHRNB4 1075/4885CHRNA3 1678/4885CHRNB2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.